Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 6, 2011, Pages 581-587

  Inoue, Kenji ^a   Okayama, Ryoko ^a   Higa, Risako ^a   Sawada, Hideko ^a   Wakakura, Masato ^a   Tomita, Goji ^b  

^a Nishikasai Inouye Eye Hospital   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; RYSMON TG; TIMOLOL MALEATE; TIMOPTOL XE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; QUESTIONNAIRES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 83455255120     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0057     Document Type: Article

References (18)

1. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
3. Djafari, F., Lesk, M.R., Harasymowycz, P.J., Desjardins, D., and Lachaine, J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J. Glaucoma 18:238-243, 2009.
4. Polo, V., Larrosa, J.M., Ferreras, A., et al. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma. Ann. Ophthalmol. 40:157-162, 2008.
5. Dunker, S., Schmucker, A., Maier, H., and Latanoprost/Timolol Fixed Combination Study Group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv. Ther. 24:376-386, 2007. (Pubitemid 46988382)
6. Hamacher, T., Schinzel, M., Schölzel-Klatt, A., et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br. J. Ophthalmol. 88:1295-1298, 2004. (Pubitemid 39312975)
7. Diestelhorst, M., Larsson, L.I., and the European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 88:199-203, 2004. (Pubitemid 38142086)
8. Diestelhorst, M., Larsson, L.I., and the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 113:70-76, 2006. (Pubitemid 43021730)
9. Rossi, G.C., Pasinetti, G.M., Bracchino, M., et al. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. Expert. Opin. Pharmacol Ther. 10:1705-1711, 2009.
10. Arend, KO., and Raber, T. Observational study in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany. J. Ocul. Pharmacol. Ther. 24:414-420, 2008.
11. Rhee, D.J., Peace, J.H., Mallick, S., et al. A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 2:313-319, 2008.
12. Konstas, A.G.P., Nakos, E., Tersis, I., et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/ timolol. Am. J. Ophthalmol. 113:753-757, 2002. (Pubitemid 34580621)
13. Takamaz, T., Asik, S., Kurkcuoglu, P., Gurdal, C., and Can, I. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol mateate combination. Eur. J. Ophthalmol. 18:60-65, 2008. (Pubitemid 351428550)
14. Kitazawa, Y., and KP2035 Study Group. Phase 3 doubleblind study of latanoprost/timolol combination (KP2035) in patients with primary open-angle glaucoma or ocular hypertension. Jpn. J. Clin. Opthalmol. 63:807-815, 2009.
15. Higginbotham, E.J., Olander, K.W., Kim, E.E., et al. Fixed combination of latanoprost and timolol vs indivisual conponents for primary open-glaucoma or ocular hypertension: a randomized, double-masked study. Arch. Ophthalmol. 128:165-172, 2010.
16. Pfeiffer, N., and European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its indivisual components. Graefes. Arch. Clin. Exp. Ophthalmol. 240:893-899, 2002. (Pubitemid 36097111)
17. Konstas, A.G., Boboridis, K., Tzetzi, D., et al. Twenty-fourhour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch. Ophthalmol. 123:898-902, 2005. (Pubitemid 41057985)
18. Beckers, H.J.M., Schouten, J.S.A.G., Webers, C.A.B., Valk, R., and Hendrikse, F. Side effects of commonly used glaucoma medications: comparison to tolerability, chance of discontinuation, and patient satisfaction. Graefes. Arch. Clin. Exp. Ophthalmol. 246:1485-1490, 2008.